2nd Quarter - Report
ARENTFOX SCHIFF LLP for KEMPHARM, INC.
Firm
Client
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
FDA regulation of opioid abuse deterrent formulations H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| NORMAN FREDERICK LENT | — |
Health Issues HCR
Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| NORMAN FREDERICK LENT | — |
| SONJA NESBIT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.